Sagittarius Life Science Corp. (3205) AI Stock Analysis

Sagittarius Life Science Corp.

(TPEx:3205)

Select Model

Rating:41Neutral

Price Target:TWD 42.00▼(-6.25% Downside)

Action:initiatedcoverage

Date:11/09/26

Sagittarius Life Science scores low primarily because of weak operating fundamentals: revenue has declined roughly 18% to about NT$346 million, gross margins are thin, and the company has never posted positive operating profit or operating cash flow in the period shown, burning about NT$36 million in cash last year. The key offset is a near debt-free balance sheet with roughly NT$1.04 billion of equity following a large capital raise, which provides a multi-year funding runway and has coincided with narrowing losses and burn — though at the cost of shareholder dilution. Technicals reinforce the caution, with the stock below all major moving averages and negative MACD momentum, while a negative P/E and no dividend leave valuation unsupportive. The investment case rests entirely on management stabilizing revenue and reaching breakeven before the new capital is consumed.

Positive Factors

Low LeverageMinimal leverage gives the company greater financial flexibility than a highly indebted biotechnology peer. It can preserve borrowing capacity for research and operations, while facing less interest burden and refinancing pressure if business conditions remain difficult.

Negative Factors

Revenue ContractionRecent revenue contraction points to weak commercial traction and makes it harder for the company to absorb its operating cost base. Continued top-line volatility could restrict investment capacity, delay scale benefits, and prolong the path toward sustainable profitability.

Sagittarius Life Science Corp. (3205) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 3.01B
Dividend Yield: ―
Average Volume (3M): 31.72K
Price to Earnings (P/E): -196.0
Beta (1Y): 0.56
Revenue Growth: 4.86%
EPS Growth: 83.87%
Country: TW
Employees: 112
Sector: General
Sector Strength: 55
Industry: Biotechnology

Sagittarius Life Science Corp. Business Overview & Revenue Model

Company Description

Sagittarius Life Science Corp, established in 1998 and headquartered in Taipei, Taiwan, focuses on the innovation, development, and sale of both traditional Chinese and modern Western pharmaceuticals, alongside nutritional supplements. Its market rea...

Sagittarius Life Science Corp. Financial Statement Overview

Summary

Financials show a classic development-stage biotech profile: a very strong, essentially debt-free balance sheet (score 76) with equity more than doubling to about NT$1.04 billion after a sizeable capital raise, offset by weak earnings (income statement score 23) and persistent cash burn (cash flow score 27). Revenue fell roughly 18% to about NT$346 million, continuing a multi-year decline from the 2021 peak, gross margin is thin at about 16.7%, and the company posted an operating loss near NT$59 million with negative EBITDA. Operating and free cash flow remained negative at roughly -NT$36 million, though both losses and burn have narrowed for a second straight year. The fortified balance sheet buys a multi-year runway, but dilution and the absence of any profitable or cash-generative year keep the overall financial score low.

Income Statement

23Negative

Balance Sheet

76Positive

Cash Flow

27Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	467.69M	346.08M	467.75M	440.46M	529.07M	587.61M
Gross Profit	42.12M	57.71M	81.11M	71.48M	82.56M	100.54M
EBITDA	-19.89M	-48.16M	-34.72M	-41.71M	-55.40M	-65.92M
Net Income	-16.84M	-49.56M	-48.53M	-55.04M	-74.20M	-86.42M
Balance Sheet
Total Assets	1.14B	1.07B	519.83M	664.72M	579.12M	675.75M
Cash, Cash Equivalents and Short-Term Investments	635.12M	803.55M	160.90M	215.38M	269.72M	358.91M
Total Debt	73.60M	385.00K	10.77M	13.32M	11.37M	24.00M
Total Liabilities	134.44M	26.91M	100.07M	137.82M	123.70M	144.03M
Stockholders Equity	1.00B	1.04B	408.35M	514.65M	441.79M	516.77M
Cash Flow
Free Cash Flow	-261.16M	-36.45M	-48.28M	-71.38M	-53.98M	-37.61M
Operating Cash Flow	-210.21M	-36.05M	-44.48M	-69.37M	-52.89M	-29.18M
Investing Cash Flow	154.13M	-558.62M	2.73M	22.45M	-1.14M	-104.82M
Financing Cash Flow	66.07M	662.89M	-9.89M	-7.89M	-13.16M	-4.16M

Sagittarius Life Science Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:3205 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1783	76Outperform	TWD 3.16B	9.38	―	5.55%	8.14%	29.10%
TW:1752	65Neutral	TWD 3.02B	16.07	―	5.35%	-6.10%	-26.89%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6461	42Neutral	TWD 2.94B	-5.62	―	―	-57.87%	-21.67%
TW:3205	41Neutral	TWD 3.01B	-195.98	―	―	4.86%	83.87%

* General Sector Average

Performance Comparison

TW:3205 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:3205	Sagittarius Life Science Corp.	44.80	-2.35	-4.98%
TW:1752	Nang Kuang Pharmaceutical Co., Ltd.	29.90	-6.84	-18.62%
TW:1783	Maxigen Biotech Inc.	36.00	-6.54	-15.37%
TW:6461	Intech Biopharm Ltd	26.20	1.30	5.24%
TW:6838	Formosa Pharmaceuticals, Inc.	20.35	-7.10	-25.87%
TW:7427	Great Novel Therapeutics Biotech & Medicals Corp.	59.00	20.91	54.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Sagittarius Life Science Corp. AI Stock Analysis